BIO-TECHNE Corp vs Vanguard Real Estate Index Fund ETF — how do they compare? BIO-TECHNE Corp trades at $72.46 (market cap $11.36B), while Vanguard Real Estate Index Fund ETF trades at $90 (market cap $70.80B). The key difference: Vanguard Real Estate Index Fund ETF is far larger — about 6.2× BIO-TECHNE Corp's market cap, and BIO-TECHNE Corp pays a 0.44% dividend while Vanguard Real Estate Index Fund ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold BIO-TECHNE Corp for 63 Days and Vanguard Real Estate Index Fund ETF for 112 Days on average.
| TECH | VNQ | |
|---|---|---|
Market Cap | $11.36B | $70.80B |
Volume | 5,390,331 | 6,073,580 |
Sector | Health | — |
52-Week High | $72.61 | $100.95 |
52-Week Low | $43.31 | $87.00 |
Typical Hold Time | 63 Days | 112 Days |
Enterprise Value | $11.39B | — |
Dividend Yield | 0.44% | — |
Signals from Pluang's Aura AI — not financial advice
TECH trades at $72.53, near its 52-week high of $72.70, with a bullish technical signal from moving averages. The company reported mixed quarterly earnings, beating in Q4 2025 and Q2 2026 but missing in Q1 2026. Revenue for 2025 was $1.22B, with a net income margin of 14.97%. Valuation ratios are elevated, with a P/E of 62.46 and P/S of 9.36. A significant development is the shareholder-approved acquisition by Merck KGaA at $73.00 per share, pending completion.
The outlook is heavily influenced by the pending acquisition, offering a near-term price ceiling. Fundamentals show solid profitability but high valuation multiples. Risks include acquisition deal completion uncertainty and integration challenges. Analyst sentiment is mixed with no sell ratings, but the consensus price target of $65.78 suggests limited upside from current levels, making the stock a hold pending acquisition closure.
VNQ (Vanguard Real Estate ETF) trades at $88.69, down 1.38% on the day amid a bearish technical signal, with moving averages indicating a downtrend. Recent news highlights a sharp sector decline due to rising Treasury yields and Fed rate hikes, eroding its income appeal versus safer assets. The ETF's financial ratios are not applicable as it is a fund tracking REITs, but it offers a dividend yield with a recent $0.80 distribution scheduled for September 2026.
Outlook remains cautious with high interest rates pressuring REIT valuations, though contrarian investors see opportunity in oversold conditions. Risks include sustained rate hikes and economic slowdowns, while potential upside hinges on a Fed pivot. Institutional buying, such as State Street's recent share increase, suggests some confidence in long-term value.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Read more on TECH →The fund employs an indexing investment approach designed to track the performance of the MSCI US Investable Market Real Estate 25/50 Index, an index made up of stocks of large, mid-size, and small US companies within the real estate sector. The Advisor attempts to replicate the target index by seeking to invest all of its assets in the stocks that make up the index, in order to hold each stock in approximately the same proportion as its weighting in the index. It is non-diversified.
Read more on VNQ →